CORTICOTROPIN AND CORTICOSTEROIDS IN GENERALIZED MYASTHENIA GRAVIS: COMPARATIVE STUDIES AND ROLE IN MANAGEMENT

Annals of the New York Academy of Sciences

Volumn 274, Issue 1, 1976, Pages 577-595

  Brunner, Norman G ^a,b   Berger, Charles L ^a,b   Namba, Tatsuji ^a,b   Grob, David ^a,b  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; PREDNISONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPARATIVE STUDY; DRUG ADMINISTRATION; EYE DISEASE; FEMALE; HUMAN; MALE; MYASTHENIA GRAVIS; THYMECTOMY; TIME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; CHILD; COMPARATIVE STUDY; CORTICOTROPIN; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; EYE DISEASES; FEMALE; HUMAN; MALE; MIDDLE AGE; MYASTHENIA GRAVIS; PREDNISONE; THYMECTOMY; TIME FACTORS;

EID: 0016908279     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1976.tb47717.x     Document Type: Article

References (49)

1. Corticotropin in generalized myasthenia gravis: Effect of short, intensive courses
2. Studies in myasthenia gravis: Shortterm massive corticotropin therapy
3. Treatment of severe myasthenia gravis with large doses of ACTH
4. Corticotropin therrpy in myasthenia gravis: Effects, indications and limitations
5. Corticotropin therapy and thymectomy in management of myasthenia gravis
6. Treatment of myasthenia gravis with adrenocorticotropic hormone (ACTH): Massive short‐term and maintenance treatment
7. Role of adrenocorticosteroids in mediation of therapeutic effect of corticotropin in severe generalized myasthenia gravis
8. Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration. Bull.
9. Corticosteroids in management of severe generalized myasthenia gravis: Effectiveness and comparison with corticotropin therapy
10. The treatment of severe myasthenia gravis with immunosuppressive agents
11. Myasthenia gravis and myasthenic syndromes treated with prednisone
12. Continuous treatment of myasthenia gravis with prednisone
13. Benefit from alternate day prednisone in myasthenia gravis
14. Treatment of myasthenia gravis with prednisone
15. Use of corticotropin and corticosteroids in the management of severe generalized myasthenia gravis
16. Long‐term administration of prednisone in myasthenia gravis
17. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment
18. Short intensive courses of dexamethasone in myasthenia gravis
19. Prednisone schedule for myasthenia gravis
20. Adverse interaction between steroid hormones and anticholinesterase drugs
21. Myasthenia gravis
22. Alternate day versus shorter interval steroid administration
23. Peptic ulcer in myasthenia gravis
24. Certain endocrine and metabolic facets of the steroid withdrawal syndrome
25. Acute arthralgia following high‐dose intravenous methylprednisolone therapy
26. Acute arthralgia after high‐dose intravenous methylprednisolone
27. Hyperlipoproteinemia associated with prednisone therapy
28. Corticotropin in treatment of ocular myasthenia: A controlled clinical trial
29. Treatment of ocular myasthenia gravis with corticotropin
30. Ocular response to corticotropin in myasthenia gravis
31. Oral corticosteroids in the treatment of ocular myasthenia gravis
32. Corticotropin therapy in patients with myasthenia gravis: Electrophysiologie, pharmacologic studies
33. EMG analysis of myasthenic deterioration
34. Cortisone effects on myoneural junction
35. The effect of corticoropin on the neuromuscular junction: Morphologic studies in rabbits
36. Corticosteroids: A direct effect at the neuromuscular junction
37. Myasthenia gravis–New hypothesis
38. Changes in serum complement activity in patients with myasthenia gravis
39. Effect of serum and serum globulin of patients with myasthenia gravis on neuromuscular transmission
40. Neonatal myasthenia gravis: Report of two cases and review of the literature
41. Serum globulin in myasthenia gravis: Inhibition of α‐bungarotoxin binding to acetylcholine receptors
42. Effect of pituitary adrenotropic hormone on lymphoid tissue
43. Similarity of response of thymus and lymph nodes to administration of adrenocorticotropic hormone in the rat
44. Effect of adrenotrophic hormone of pituitary gland on ability of tissue to synthesize acetylcholine
45. Effects of corticosterone, hydrocortisone and corticotropin on production of antibodies in rabbits
46. Effect on mice of intravenous administration of lymphocytes from normal subjects and from patients with myasthenia gravis
47. Lymphocytes of patients with myasthenia gravis. Local effects in rats following intramuscular administration
48. Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor